key: cord-0995990-s3nsm16v
authors: Rusanen, J.; Kareinen, L.; Szirovicza, L.; Ugurlu, H.; Levanov, L.; Jaaskelainen, A. E.; Ahava, M.; Kurkela, S.; Saksela, K.; Hedman, K.; Vapalahti, O.; Hepojoki, J.
title: A generic, scalable, and rapid TR-FRET -based assay for SARS-CoV-2 antigen detection
date: 2020-12-07
journal: nan
DOI: 10.1101/2020.12.07.20245167
sha: 84410bc9b17a36fb13d801eb04b56896235e0db6
doc_id: 995990
cord_uid: s3nsm16v

The ongoing COVID-19 pandemic has seen an unprecedented increase in the demand for rapid and reliable diagnostic tools, leaving many laboratories scrambling for resources. We present a fast and simple method for the detection of SARS-CoV-2 in nasopharyngeal swabs. The method is based on the detection of SARS-CoV-2 nucleoprotein (NP) and S protein (SP) via time-resolved Foerster resonance energy transfer (TR-FRET) with donor- and acceptor-labeled polyclonal anti-NP and -SP antibodies. Using recombinant proteins and cell culture-grown SARS-CoV-2 the limits of detection were established as 25 pg of NP or 20 infectious viral units (i.u.), and 875 pg of SP or 625 i.u. of SARS-CoV-2. Testing RT-PCR positive (n=48, with cycle threshold [Ct] values from 11 to 30) or negative (n=96) nasopharyngeal swabs, we showed that the assay yields positive results for all samples with Ct values of <25 and a single RT-PCR negative sample. We determined the presence of infectious virus in the RT-PCR-positive nasopharyngeal swabs by virus isolation, and observed a strong association between the presence of infectious virus and a positive antigen test result. The NP-based assay showed 97.4% (37/38) sensitivity and 100% (10/10) specificity in comparison with virus isolation, and 77.1% (37/48) and 99.0% (95/96) in comparison with SARS-CoV-2 RT-PCR. The assay is performed in a buffer that neutralizes SARS-CoV-2 infectivity and is relatively simple to set up as an "in-house" test. The assay principle as such is applicable to other viral infections, and could also be readily adapted to a massively high throughput testing format.

The ongoing coronavirus disease 2019 (COVID-19) pandemic has by December 2020 47 claimed almost one and a half million lives globally, with over 60 million confirmed infections. 48 To manage the disease, accurate diagnostic tools are of key importance. Detection of the 49 causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or its 50 parts is the cornerstone of diagnosis, as the disease presentation is often indistinguishable from 51 other respiratory infections. The mainstay of COVID-19 diagnosis is RT-PCR testing, done 52 typically from a nasopharyngeal swab (NPS), while also oropharyngeal or mid-turbinate swab 53 as well as salivary samples are in use. Alternatively, the less labour-intensive antigen detection 54 tests are also increasingly deployed. Antigen tests tend to be specific, but analytically less is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 7, 2020. ; https://doi.org/10.1101/2020.12.07.20245167 doi: medRxiv preprint 4 2020 received emergency use authorization (EUA) from the U.S. Food and Drug 71 Administration (FDA), six target N and one S 7 . 72 Over the past few years, we have actively employed time-resolved Förster resonance energy 73 transfer (TR-FRET) as basis of rapid homogeneous "mix and read" immunoassays for antibody 74 detection [8] [9] [10] [11] [12] [13] [14] . FRET occurs when a donor and an acceptor fluorophore are in close proximity, 75 whereby the excited donor transfers energy to the acceptor, which then emits a photon at a 76 distinct wavelength. The closer the donor and acceptor are, the more frequent is the energy 77 transfer, with a 50% efficiency typically achieved at a distance of 15 to 60 Å. Chelated is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 7, 2020. ; https://doi.org/10.1101/2020.12.07.20245167 doi: medRxiv preprint

The evaluation of the SARS-CoV-2 TR-FRET assay was conducted by using 92 nasopharyngeal swab (NPS) specimens collected in saline. The specimens were retrieved from 93 patients with a clinically suspected COVID-19 and they were originally sent to HUS Diagnostic 94 Center, HUSLAB for SARS-CoV-2 RT-PCR testing. The specimens were subsequently stored 95 at -20°C.

The SARS-CoV-2 RT-PCR was based on a laboratory-developed test (LDT). The details 97 and performance of the test in our laboratory setting have been described previously 15 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 7, 2020. supplemented with 10% fetal bovine serum (FBS, Gibco), 100 IU penicillin and 100 µg/ml 129 streptomycin (Sigma), and 2 mM L-glutamine (Sigma). For isolation, the cells were grown on 130 12-well plates until approximately 90% confluent, the growth medium replaced with 400 µl of 131 MEM-2% (as above but with 2% FBS), followed by addition of 50 µl of the NPS sample (under 132 biosafety level 3 conditions), and 1 h incubation at 37°C 5% CO2. After two washes with MEM-133 2%, cultures were kept in 1 ml fresh MEM-2% for 4 days at 37°C (5% CO2), the medium is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 7, 2020. ; https://doi.org/10.1101/2020.12.07.20245167 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 7, 2020. ; https://doi.org/10.1101/2020.12.07.20245167 doi: medRxiv preprint 8 8.0, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate and Roche cOmplete 164 EDTA-free protease inhibitor cocktail).

Antigens and antibodies 166 The production and purification of SARS-CoV-2 NP and SP antigens, followed a described 167 protocol 14,19,20 . The RBD of the SP was produced in Expi293F cells as described 19, 20 . Rabbit is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 7, 2020. ; https://doi.org/10.1101/2020.12.07.20245167 doi: medRxiv preprint 9 anti-NP antibodies. The assay principle and workflow are depicted in Fig. 1 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 7, 2020. ; https://doi.org/10.1101/2020.12.07.20245167 doi: medRxiv preprint the TR-FRET assays performed as above at Eu-and AF-labeled anti-NP/-RBD concentrations 214 of 6 + 6 nM.

The NPS sample analysis was done by mixing 10 µl of the sample with 10 µl of the antibody is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 7, 2020. ; https://doi.org/10.1101/2020.12.07.20245167 doi: medRxiv preprint

Proof-of-concept for the homogeneous antigen detection assay 224 We hypothesized that homogenous i.e. in solution detection of antigens could be achieved 225 utilizing a polyclonal antibody separately labelled with fluorophores forming a FRET pair. To 226 test the hypothesis and assay principle presented in Fig. 1 , we generated antisera against SARS-227 CoV-2 NP and the RBD of SP, titers >204,800 based on NP and SP ELISA respectively.

Following affinity purification, the antibodies were labelled with chelated europium (Eu, is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 7, 2020. ; https://doi.org/10.1101/2020.12.07.20245167 doi: medRxiv preprint 2.5 nM of AF647-labeled) it took ~60 min for the signal to peak for both NP and SP, whereas 249 in an antibody concentration of 500 nM, the NP signal peak occurred in 7 min and the SP signal 250 peaked in ~30 minutes. We also tested the assay performances with Eu-and AF-labeled 251 antibodies mixed at the unequal proportions of 1:2 and 2:1, but this did not increase the signal 252 to background ratio (Table S1) . 253 We then evaluated the assay performance at 50, 25, 12, and 6 nM total antibody 254 concentrations using SARS-CoV-2 containing cell culture supernatants at different dilutions. 255 We included a UV-inactivated cell culture supernatant to find out whether UV inactivation To assess the limits of detection (LOD) for the assays at 12 nM total antibody concentration, 263 we spiked a pool of NPS samples with either purified antigens or inactivated SARS-CoV-2 at 264 different dilutions. With purified antigens, the lowest concentrations producing readily 265 detectable signals were 0.05 nM for NP and 0.5 nM for SP (Fig. S4, a-b) . With UV-inactivated 266 SARS-CoV-2, dilutions of the supernatant up to 1:5120 and 1:160 produced reliably 267 measurable signals with anti-NP and anti-RBD antibodies, respectively (Fig. S4, c-d) . With the 268 10 µl sample volume, the detection limit of the assay for recombinant NP was ~25 pg (using 269 molecular weight of 50 kDa) and 875 pg for the SP (using molecular weight of 175 kDa). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 7, 2020. from ~12 to 30 (Fig. S5) , and employed total antibody concentrations of 50, 25, 12, and 6 nM. 278 We observed that samples with Ct values of ≤25 yielded a signal in the NP assay (Fig. S6) . By is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 7, 2020. ; https://doi.org/10.1101/2020.12.07.20245167 doi: medRxiv preprint 14 >24.5 all produced a negative result in the TR-FRET NP assay, and SARS-CoV-2 was 299 recovered from only one (Ct 24.87). By using the optimized conditions with 12 nM total labeled 300 antibodies, the sensitivity of NP assay in comparison with virus isolation was 97.4% (37/38).

The performance of the SP assay was poorer; only 8/38 samples with recoverable SARS-CoV-302 2 yielded a positive result (Fig. 2b) . To assess the antigen-specificity of the signal, we also analyzed this sample using mismatching nor hCoV-NL63 yielded a significant TR-FRET signal in either NP or SP assay (Fig. 3) . The is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 7, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 7, 2020. ; https://doi.org/10.1101/2020.12.07.20245167 doi: medRxiv preprint to Fig. S7 ), which additionally contributed to the higher sensitivity of NP detection in cell 348 culture supernatants and NPS samples. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 7, 2020. ; https://doi.org/10.1101/2020.12.07.20245167 doi: medRxiv preprint signal. The use of miss-matching antibodies could be in the future serve to discern true and 373 false positives in the TR-FRET assay.

In conclusion, we report the development of a rapid SARS-CoV-2 antigen test based on 375 simultaneous binding of two or more fluorophore-labeled antibody molecules to the antigen.

The TR-FRET -based antigen test is rapid to perform, and its results correlate well with the 377 presence of infectious virus in clinical sample. The assay is easy to set up, if a suitable antibody 378 against SARS-CoV-2 NP and a plate reader enabling TR-FRET measurement are available. 379 We estimate that a single plate reader and an experienced technician could manually analyze 380 hundreds of specimens per hour, ideally with a 30-minute turn-around time from sample arrival 381 to results (see supplementary information for details). The assay throughput could significantly 382 be up scaled by using automation, and alike RT-PCR the sample collection would represent the 383 major limiting factor. The NPS sampling directly to a detergent-containing buffer increases the 384 assay's user-safety. We envision that the assay could be applied widely in the field, e.g. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 7, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 7, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 7, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 7, 2020. ; https://doi.org/10.1101/2020.12.07.20245167 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 7, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 7, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 7, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 7, 2020. ; https://doi.org/10.1101/2020.12.07.20245167 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 7, 2020. ; https://doi.org/10.1101/2020.12.07.20245167 doi: medRxiv preprint 27   Table S1 . Comparison of TR-FRET antigen assay results, expressed as HTRF ratio 534 (HTRFsample/HTRFbuffer), using different ratios of Eu-and AF647-labeled anti-NP and anti- is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 7, 2020. ; https://doi.org/10.1101/2020.12.07.20245167 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 7, 2020. ; https://doi.org/10.1101/2020.12.07.20245167 doi: medRxiv preprint 29 549 Figure S4 . The limit of detection for TR-FRET antigen detection using NPS samples spiked is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 7, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 7, 2020. ; https://doi.org/10.1101/2020.12.07.20245167 doi: medRxiv preprint

Presymptomatic SARS-CoV-2 infections and transmission in a skilled

The authors wish to acknowledge Drs. Sisko Tauriainen (University of Turku, Turku, 390 Finland) and Lia van der Hoek (Academic Medical Center, Amsterdam, Netherlands) for

providing the human coronaviruses used for evaluating cross-reactivity. The study was 392 supported by Academy of Finland (grants 308613, 314119, and 335762 to JH).

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted December 7, 2020. ; https://doi.org/10.1101/2020.12.07.20245167 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted December 7, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted December 7, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted December 7, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted December 7, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted December 7, 2020. ; https://doi.org/10.1101/2020.12.07.20245167 doi: medRxiv preprint